Results 21 to 30 of about 119,907 (304)

Probing the Pharmacological Binding Properties, and Reactivity of Selective Phytochemicals as Potential HIV-1 protease Inhibitors

Universitas Scientiarum, 2019
The HIV-1 protease plays an essential role in the replication cycle of HIV-1; therefore there is a direct need to develop novel inhibitors of the HIV-1 protease, which can cease the viral replication.
Ammara Akhtar, Waqar Hussain, Nouman Rasool3
doaj   +1 more source

Proteochemometric modeling of HIV protease susceptibility

BMC Bioinformatics, 2008
Background A major obstacle in treatment of HIV is the ability of the virus to mutate rapidly into drug-resistant variants. A method for predicting the susceptibility of mutated HIV strains to antiviral agents would provide substantial clinical benefit ...
Prusis Peteris, Spjuth Ola, Eklund Martin, Lapins Maris, Wikberg Jarl ES   +4 more
doaj   +1 more source

The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study

BMC Cancer, 2021
Background The incidence of anal squamous cell carcinoma has been increasing, particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs, such as protease inhibitors, commonly used in the management of HIV, may increase ...
Alison K. Yoder, David S. Lakomy, Yongquan Dong, Suchismita Raychaudhury, Kathryn Royse, Christine Hartman, Peter Richardson, Donna L. White, Jennifer R. Kramer, Lilie L. Lin, Elizabeth Chiao   +10 more
doaj   +1 more source

Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors [PDF]

, 2008
Poster presentation: Purpose of the study To compare the lipometabolic profiles of three double-boosted protease inhibitor (PI) regimens at standard dose, containing saquinavir and ritonavir in combination with lopinavir (LOPSAQ), atazanavir (ATSAQ) or ...
Bickel, Markus, Hentig, Nils von, Khaykin, Pavel, Knecht, Gaby, Lennemann, Tessa, Lutz, Thomas, Staszewski, Schlomo, Stephan, Christoph, Wendig, Annette   +8 more
core   +1 more source

Oral Thrush and HIV Protease Inhibitors

Journal of Acquired Immune Deficiency Syndromes, 1999
Roberto Cauda, Antonio Cassone
openalex   +4 more sources

Antileishmanial activity of HIV protease inhibitors [PDF]

International Journal of Antimicrobial Agents, 2005
The proteasomes of some protozoa are possible targets for chemotherapy. Leishmaniasis is a major health problem in human immunodeficiency virus (HIV) co-infected subjects. Two HIV protease inhibitors (PI), indinavir and saquinavir, have been shown to block proteasome functions; we therefore investigated their effects on the growth of two Leishmania spp.
SAVOIA, Dianella, T. ALLICE, TOVO, Pier Angelo   +2 more
openaire   +3 more sources

New antiretroviral drugs [PDF]

, 2003
Despite the availability of 16 antiretroviral drugs approved for the treatment of HIV infection, current combination regimens present challenges. Newer antiretroviral drugs are needed to improve convenience, reduce toxicity and, of particular importance,
Gulick, R.M.
core   +1 more source

Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease

Biology, 2012
Designing HIV-1 protease inhibitors that overcome drug-resistance is still a challenging task. In this study, four clinical isolates of multi-drug resistant HIV-1 proteases that exhibit resistance to all the US FDA-approved HIV-1 protease inhibitors and ...
Ladislau C. Kovari, Iulia A. Kovari, Joseph S. Brunzelle, Samuel J. Reiter, Zhigang Liu, Tamaria G. Dewdney, Yong Wang   +6 more
doaj   +1 more source

Accessory mutations balance the marginal stability of the HIV-1 protease in drug resistance

, 2020
The HIV-1 protease is a major target of inhibitor drugs in AIDS therapies. The therapies are impaired by mutations of the HIV-1 protease that can lead to resistance to protease inhibitors.
Hemmateenejad, B., Weikl, T.
core   +1 more source

Molecular Basis for Drug Resistance in HIV-1 Protease

Viruses, 2010
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the ...
Celia A. Schiffer, Kelly Thayer, Ellen A. Nalivaika, Ayşegül Özen, Moses M. Prabu-Jeyabalan, Madhavi N.L. Nalam, Nancy M. King, Rajintha M. Bandaranayake, Jennifer F. Murzycki, Seema Mittal, Madhavi Kolli, Yufeng Cai, Akbar Ali   +12 more
doaj   +1 more source